- Home
- RNTX vs AXIL Comparison
RNTX vs AXIL Comparison
Compare RNTX & AXIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNTX
- AXIL
- Stock Information
- Founded
- RNTX 2001
- AXIL 2015
- Country
- RNTX United States
- AXIL United States
- Employees
- RNTX N/A
- AXIL N/A
- Industry
- RNTX Biotechnology: Pharmaceutical Preparations
- AXIL Package Goods/Cosmetics
- Sector
- RNTX Health Care
- AXIL Consumer Discretionary
- Exchange
- RNTX Nasdaq
- AXIL Nasdaq
- Market Cap
- RNTX 34.6M
- AXIL 36.8M
- IPO Year
- RNTX N/A
- AXIL N/A
- Fundamental
- Price
- RNTX $1.43
- AXIL $5.63
- Analyst Decision
- RNTX Buy
- AXIL
- Analyst Count
- RNTX 2
- AXIL 0
- Target Price
- RNTX $10.00
- AXIL N/A
- AVG Volume (30 Days)
- RNTX 114.1K
- AXIL 15.3K
- Earning Date
- RNTX 11-13-2025
- AXIL 10-07-2025
- Dividend Yield
- RNTX N/A
- AXIL N/A
- EPS Growth
- RNTX N/A
- AXIL N/A
- EPS
- RNTX N/A
- AXIL 0.15
- Revenue
- RNTX N/A
- AXIL $27,262,468.00
- Revenue This Year
- RNTX N/A
- AXIL N/A
- Revenue Next Year
- RNTX N/A
- AXIL N/A
- P/E Ratio
- RNTX N/A
- AXIL $38.57
- Revenue Growth
- RNTX N/A
- AXIL 0.07
- 52 Week Low
- RNTX $1.04
- AXIL $3.54
- 52 Week High
- RNTX $4.40
- AXIL $10.75
- Technical
- Relative Strength Index (RSI)
- RNTX 60.90
- AXIL 44.12
- Support Level
- RNTX $1.22
- AXIL $5.92
- Resistance Level
- RNTX $1.30
- AXIL $6.97
- Average True Range (ATR)
- RNTX 0.11
- AXIL 0.49
- MACD
- RNTX 0.00
- AXIL 0.07
- Stochastic Oscillator
- RNTX 66.15
- AXIL 31.63
About RNTX Rein Therapeutics Inc. Common Stock
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.
About AXIL AXIL Brands Inc. Common Stock
AXIL Brands Inc is a company which is is a manufacturer and marketer of premium hearing enhancement and protection products, including ear plugs, earmuffs, and ear buds, and outdoor speakers, under the AXIL brand. AXIL delivers top hearing enhancement, protection, & audio devices. From ultra comfortable fitting processes, to stereo quality sound performance, to reliable & durable engineering. The company operates two operating segments: hearing enhancement and protection, and hair and skin care.